A number of side effects of uremia have become significant due to the increased life expectancy brought about by the success of dialytic support for end-stage renal disease (ESRD). Anemia, of multifactorial etiology, is symptomatically one of the most significant; often it is treated only with transfusions. These transfusions eventually may be associated with iron overload, or 'transfusional hemosiderosis,' in the ESRD population. In a transfusion-dependent ESRD patient, the only viable treatment for this iron overload has been chelation with deferoxamine (DFO), used for this purpose. Intraperitoneal (IP) administration of DFO has been used and published in case studies. This paper reports on a study to establish the potential for removal of iron via a protocol avoiding multiple daily continuous ambulatory dialysis patients bag manipulations. Study methods and results are discussed.
|Original language||English (US)|
|Number of pages||3|
|State||Published - Jul 1 1987|
ASJC Scopus subject areas